AVEO Pharmaceuticals (AVEO) Tops Q3 EPS by 23c, Offers Gudiance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
AVEO Oncology Reports Third Quarter 2015 Financial Results and Provides Business Update
November 9, 2015 6:30 AM ESTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update.
We completed partnerships for two of AVEOs lead programs in the third quarter in addition to making progress toward our proposed plans to submit a European Marketing Authorization Application (MAA) for tivozanib in renal cancer and initiate a pivotal study in this indication in the U.S., said Michael Bailey, president and chief executive officer. As we work through recently initiated discussions with the SEC, we remain focused on... More
